Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
MedTech

Emerging Pharma Companies in Ireland to Watch in 2026

Sreepriya Prasannan
Sreepriya Prasannan

NewsWritten by our team from the primary sources linked below. Reviewed, verified and approved by a human editor. How we check

Speed:
Emerging Pharma Companies in Ireland to Watch in 2026

The Irish life sciences sector-spanning biotechnology, pharmaceuticals, and medtech-has consistently remained a dominant force in the global startup ecosystem. As we move deeper into 2026, Ireland continues to produce world-class innovation fueled by highly skilled talent, world-renowned research institutions, and robust financial backing from state agencies like Enterprise Ireland and the Disruptive Technologies Innovation Fund (DTIF).

Following a record-setting €491.3 million raised across venture capital deals in recent years, the Irish ecosystem has transitioned from a hub of early-stage startups to a breeding ground for global scale-ups. In this comprehensive report, we highlight the Top 5 Emerging Pharma and MedTech Companies in Ireland to Watch in 2026. These are indigenous Irish companies currently in a hyper-growth stage, poised to become the next massive players in the industry.


1. LetsGetChecked

Based in Dublin, LetsGetChecked has evolved from a disruptive startup into a global leader in at-home health testing, diagnostics, and telehealth services. As healthcare continues to decentralize, their platform provides patients with clinical-grade testing from the comfort of their homes.

A photorealistic mock-up of an at-home medical diagnostic test kit
Representation of at-home clinical testing kits pioneered by diagnostic leaders.
  • Website: letsgetchecked.com
  • LinkedIn: LetsGetChecked LinkedIn
  • Founder & CEO: Peter Foley
  • Key Partners: Major US health insurers and Fortune 500 employers.
  • Recent Achievements: Expanded their CLIA-certified laboratories and introduced rapid genomic testing panels.
  • Funding & Support: Secured a monumental €150 million funding round in late 2025, heavily supported by prominent venture capital and historical backing from Enterprise Ireland.
Our Evaluation Metric (Why We Chose Them): Global Scaling Potential
LetsGetChecked exemplifies the highest overall growth trajectory in the Irish ecosystem. Their ability to secure nine-figure funding rounds and seamlessly penetrate the complex US healthcare market proves their model is not just innovative, but highly scalable.

2. FIRE1

FIRE1 (Foundry Innovation & Research 1) is a Dublin-headquartered connected medical device company. They are revolutionizing the management of heart failure-one of the leading causes of hospitalization globally-through an innovative, implantable sensor that monitors patients remotely.

A sleek, photorealistic medical sensor device held gently in a gloved hand
Advanced remote patient monitoring sensor technology.
  • Website: fire1med.com
  • LinkedIn: FIRE1 LinkedIn
  • Founder & CEO: Conor Hanley
  • Key Partners: Backed by major global medical device manufacturers and top-tier clinical research hospitals across Europe.
  • Recent Achievements: Successfully completed pivotal clinical trials demonstrating significant reductions in heart failure readmissions.
  • Funding & Support: Closed a massive €115 million late-stage deal in 2025, marking one of the largest health-tech investment rounds in Europe for the year.
Our Evaluation Metric (Why We Chose Them): Disruptive Clinical Impact
FIRE1 was selected due to their unparalleled clinical trial success. By directly addressing a massive unmet clinical need with a proprietary hardware-software ecosystem, they are redefining standard-of-care for cardiovascular patients.

3. Luminate Medical

Emerging from the world-class MedTech cluster in Galway, Luminate Medical is developing pioneering wearable technologies designed to prevent the devastating side effects of chemotherapy, such as chemotherapy-induced alopecia (hair loss) and peripheral neuropathy.

A high-end, photorealistic medical wearable device designed for patients
Wearable therapeutic devices designed to improve patient quality of life during oncology treatments.
  • Website: luminatemed.com
  • LinkedIn: Luminate Medical LinkedIn
  • Founders: Aaron Hannon, Dr. Barbara Oliveira, and Martin O'Halloran
  • Key Partners: National University of Ireland Galway (NUIG) and leading oncology centers in the US and UK.
  • Recent Achievements: Accelerated FDA breakthrough device designation and successful early-stage human trials.
  • Funding & Support: Raised $17 million in late 2025, heavily bolstered by grants from the Disruptive Technologies Innovation Fund (DTIF) and Enterprise Ireland's High Potential Start-Up (HPSU) program.
Our Evaluation Metric (Why We Chose Them): Patient-Centric Innovation
While many pharma companies focus purely on the drug, Luminate focuses on the patient experience. They represent the most innovative patient-centric approach emerging from Ireland, fundamentally improving the quality of life for oncology patients.

4. Deciphex

Deciphex is at the intersection of biotechnology and artificial intelligence. This Dublin-based firm is accelerating drug discovery and pathology by providing digital pathology solutions and AI-driven image analysis, drastically reducing the time it takes for pharmaceutical companies to bring drugs to market.

A photorealistic computer monitor displaying complex digital pathology slides and AI data grids
AI-powered digital pathology accelerating preclinical pharma research.
  • Website: deciphex.com
  • LinkedIn: Deciphex LinkedIn
  • Founder & CEO: Donal O'Shea
  • Key Partners: Top 10 global pharmaceutical companies and contract research organizations (CROs).
  • Recent Achievements: Launched their next-generation AI pathology platform, processing millions of slides globally.
  • Funding & Support: Consistent recipient of Enterprise Ireland innovation vouchers and R&D funding, alongside substantial private Series B/C venture backing.
Our Evaluation Metric (Why We Chose Them): AI Integration in Pharma R&D
Deciphex represents the best integration of AI into traditional pharma R&D. By digitizing and automating the pathology workflow, they are solving a major bottleneck in the trillion-dollar pharmaceutical pipeline.

5. ProVerum

Another incredible innovation story out of Dublin, ProVerum is developing a minimally invasive treatment for Benign Prostatic Hyperplasia (BPH), a condition affecting millions of men globally. Their proprietary stent technology offers a safer, outpatient alternative to traditional surgery.

A photorealistic macro shot of a delicate, minimally invasive medical stent device
Minimally invasive stent technologies transforming urology treatments.
  • Website: proverummedical.com
  • LinkedIn: ProVerum LinkedIn
  • Founder/Leadership: Dr. Paul E. Gilson (Founder) & Richard Fahy (CEO)
  • Key Partners: Clinical trial sites across Australia, Europe, and the US.
  • Recent Achievements: Unprecedented success in international clinical trials, showing rapid symptom relief with minimal side effects.
  • Funding & Support: Successfully raised €73 million in 2025 to fund pivotal global trials and prepare for full commercialization, supported by international medtech syndicates.
Our Evaluation Metric (Why We Chose Them): Rapid Commercialization Path
ProVerum was selected for their highly efficient path to market. Their regulatory successes with the FDA and EMA indicate that they are not just a research project, but a commercially viable product on the verge of widespread global adoption.

Conclusion

The convergence of state support from Enterprise Ireland, a highly educated workforce, and aggressive private capital has created an unstoppable momentum in the Irish Life Sciences sector. Keep a close eye on LetsGetChecked, FIRE1, Luminate Medical, Deciphex, and ProVerum in 2026-these companies are not just putting Ireland on the map; they are actively redrawing the boundaries of global healthcare.

Reviewed for editorial accuracy by Sreepriya Prasannan, Founder & Editor MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany
Our standards
Related from our data
Iscover 300 mg film-coated tablets — Clopidogrel hydrogensulfate · Irish Medicines Database Medical Air — Oxygen · Irish Medicines Database Medical Carbon Dioxide — Carbon dioxide · Irish Medicines Database Medical Nitrous Oxide — Nitrous oxide · Irish Medicines Database
The Effectiveness of the Twin Block and Carriere Motion Appliances in Post-pubertal Patients and an Evaluatio… — Active in Ireland · Trials Tracker Chemokeyp: A Feasibility Study for Realtime Safety Data-Capture for Potential Serious Adverse Drug Events — Recruiting in Ireland · Trials Tracker
Most-trialled drugs in our registers
Browse all trial registers →

Get the Friday brief

One email every Friday: a 60-second summary, then only the topics you choose: industry news, approvals and market access, shortages, Irish trials, careers or data, all built from public registers.

Free. Unsubscribe from any email with one click. See our privacy policy.

About the Author
Sreepriya Prasannan

Sreepriya Prasannan

Writer at Priya Life Science · MedTech

Sreepriya Prasannan is the Founder and Editor of Priya Life Science, Ireland's independent pharma, biotech and MedTech platform. She holds an MSc in Digital Transformation (Life Science) from Griffith College Dublin, with a background in QA, GMP and production operations. Shortlisted for STEM Graduate of the Year at the Business Post Women in STEM Awards 2026 and a Top 14 finalist in the HSE Spark Ignite 2026 innovation programme, she writes on regulatory trends, GMP compliance and careers across the Irish and European life sciences.

Discussion
No comments yet. Be the first to share your thoughts!
Leave a Comment